GlassScriptPhysician profile
Jonathon C Hennings
NPI 1376777383
$11,356.69
in general payments reported to CMS, 2019-2025
19 companies · $3,082 in 2025
The $3,082 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $880 · 2022: $3,744 · 2023: $525 · 2024: $3,125 · 2025: $3,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,800 · Food and Beverage: $1,549 · Travel and Lodging: $1,213 · Consulting Fee: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,800.00 |
| Food and Beverage | $1,549.49 |
| Travel and Lodging | $1,212.70 |
| Consulting Fee | $170.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $5,733.10 | 2021-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $4,538.58 | 2021-2025 | Strensiq |
| Amgen INC. | $447.42 | 2021-2025 | Evenity, Prolia, Repatha |
| Kyowa Kirin, INC. | $108.18 | 2023-2025 | Crysvita |
| Lilly USA, LLC | $89.78 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.01 | 2021-2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $53.96 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $50.88 | 2024-2025 | Voquezna |
| Pfizer INC. | $42.74 | 2022-2023 | |
| Abbvie INC. | $33.99 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $29.34 | 2025 | Smoflipid |
| Astellas Pharma US INC | $28.16 | 2023-2025 | Veozah |
| Abbott Laboratories | $21.19 | 2024 | Freestyle Libre 3 |
| Insulet Corporation | $19.16 | 2025 | Omnipod |
| Glaxosmithkline, LLC. | $18.97 | 2024 | Trelegy Ellipta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $17.21 | 2025 | Teriparatide |
| Biomarin Pharmaceutical INC. | $15.58 | 2024 | Voxzogo 1.2mg |
| Viatris Specialty LLC | $14.67 | 2025 | Yupelri |
| Novo Nordisk INC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Hennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.